Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

AstraZeneca (AZN) was upgraded to neutral from sell by UBS citing long-term support for the company in China despite ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.